Tsukuba, Japan—The advent of next-generation sequencing technologies has accelerated genome analysis across diverse eukaryotic lineages. In particular, long-read sequencing facilitates the assembly of ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for ...

What if you could flip a genetic switch to silence a gene, then turn it back on with a simple drug? For researchers, gene-switch tools offer that kind of control—and a new system called Cyclone may ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of any gene in a cell. Such "gene-switch" tools allow scientists to "turn on" ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

A man was allegedly drunk when he rear-ended another vehicle in Apple Valley late Saturday, Sept. 20, killing a man and injuring another, authorities said. The crash took place about 11:35 p.m. along ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

July 7, 2025 – The FDA has granted quick approval to a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC). The drug, called sunvozertinib and sold as Zegfrovy ...

One of the more competitive targets in lung cancer is a certain mutation that has eluded many available targeted therapies. A drug developed by Dizal Pharmaceutical has received FDA approval for ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...